🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Biocon Limited BIOCON NIFTY_MIDNSEPHARMA

Healthcare · Biotechnology · India
https://www.biocon.com
Company Profile ↓
₹434.60
+16.84% 1Y
Mkt Cap₹70,444.65 Cr
P/E154.11
P/B1.92
Div. Yield0.12%
52W High₹437.30
52W Low₹338.50
Book Value₹209.96
EPS (TTM)₹2.82

Company Overview

Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services, and other research and development in the fields of pharmaceuticals, drug discovery, biotechnology pharmaceuticals, and medicinal sciences, etc.; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 15.3% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹16,779.90 Cr (+11.5% YoY); net profit ₹385.60 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +11.5%, earnings -62.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 15.3%, profit CAGR -5.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:15.35%
1 Year:11.48%

Compounded Profit Growth

5 Years:-5.90%
1 Year:-61.95%

Stock Price Performance

1 Year:+16.84%
6 Months:+17.03%
3 Months:+21.51%
1 Month:+4.48%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 97% of range
₹338.50 ₹437.30
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)60.19 · Neutral
Price Performance
1M+4.48%
3M+21.51%
6M+17.03%
1Y+16.84%
Valuation vs Sector

P/E of 154.11 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 15.3% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 154.1.
  • Earnings shrank at -5.9% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
154.11
Industry PE
39.97
Forward P/E
37.21
PEG Ratio
-
Book Value
₹209.96
Price to Book
1.92
P/S
3.95
EV/EBITDA
23.05
Dividend Yield
0.12%

Growth (CAGR)

Revenue 5Y
15.35%
Profit 5Y
-5.90%
Revenue (YoY)
11.48%
Earnings (YoY)
-61.95%

Profitability & Returns

ROCE
2.90%
ROE
1.13%
ROA
0.61%
Profit Margin
2.30%
Op Margin
8.93%
Gross Margin
66.09%
EPS (Latest Qtr)
₹0.79
EPS (TTM)
₹2.82

Balance Sheet & Liquidity

Debt/Equity
0.45
Quick Ratio
0.79
Current Ratio
1.22
Debt
₹15,434.10 Cr
Total Assets
₹63,650.60 Cr
Current Assets
₹17,179.80 Cr
Working Capital
₹3,110.60 Cr

Ownership

Promoter Holding
53.76%
Chg in Prom Hold
0.00%
FII / Inst Holding
26.14%
Chg in FII Hold
-0.08%

Financial Snapshot

Enterprise Value
₹70,444.65 Cr
Total Revenue (TTM)
₹16,779.90 Cr
EBITDA
₹3,394.90 Cr
Free Cash Flow
₹82.30 Cr
Operating Cash Flow
₹1,994.00 Cr
Shares Outstanding
₹162.09 Cr
Gross Margin
66.09%
Payout Ratio
17.73%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 BIOCON Biocon Limited NIFTY_MIDNSEPHARMA 434.60 154.11 ₹70,444.65 Cr 0.12% 2.90% 1.13% 15.35% -5.90%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 3,774.00 Cr3,423.00 Cr3,462.00 Cr3,954.00 Cr3,917.00 Cr3,433.00 Cr3,590.00 Cr3,821.00 Cr4,358.10 Cr3,910.10 Cr4,262.50 Cr4,173.00 Cr4,484.30 Cr
Cost of Revenue --------1,472.90 Cr1,405.10 Cr1,547.00 Cr1,339.30 Cr1,399.30 Cr
Gross Profit --------2,885.20 Cr2,505.00 Cr2,715.50 Cr2,833.70 Cr3,085.00 Cr
Operating Expenses 2,817.00 Cr2,741.00 Cr2,745.00 Cr3,051.00 Cr3,004.00 Cr2,812.00 Cr2,905.00 Cr3,070.00 Cr2,243.30 Cr2,211.10 Cr2,353.10 Cr2,515.50 Cr2,578.10 Cr
Operating Income 593.00 Cr323.00 Cr328.00 Cr489.00 Cr506.00 Cr215.00 Cr265.00 Cr327.00 Cr641.90 Cr293.90 Cr362.40 Cr318.20 Cr506.90 Cr
EBITDA 957.00 Cr681.00 Cr717.00 Cr903.00 Cr913.00 Cr620.00 Cr685.00 Cr752.00 Cr1,135.50 Cr828.60 Cr916.50 Cr657.40 Cr992.40 Cr
Interest Expense 249.00 Cr233.00 Cr248.00 Cr267.00 Cr227.00 Cr236.00 Cr226.00 Cr223.00 Cr212.40 Cr276.70 Cr272.20 Cr209.90 Cr231.50 Cr
Pretax Income 497.00 Cr184.00 Cr214.00 Cr808.00 Cr319.00 Cr1,146.00 Cr98.00 Cr156.00 Cr486.80 Cr96.90 Cr171.30 Cr-67.80 Cr247.50 Cr
Tax Provision 84.49 Cr34.96 Cr40.66 Cr56.56 Cr95.70 Cr286.50 Cr70.56 Cr74.88 Cr27.40 Cr7.70 Cr38.50 Cr-16.00 Cr48.90 Cr
Net Income 414.00 Cr149.00 Cr173.00 Cr753.00 Cr223.00 Cr862.00 Cr27.00 Cr81.00 Cr344.50 Cr31.40 Cr84.50 Cr143.80 Cr125.90 Cr
Diluted EPS 2.610.841.055.501.135.49-0.130.212.870.260.651.070.79

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 3,090.00 Cr3,347.00 Cr3,891.00 Cr4,123.00 Cr5,514.00 Cr6,300.00 Cr7,143.00 Cr-10,934.10 Cr14,195.80 Cr15,052.20 Cr16,779.90 Cr
Cost of Revenue --------3,666.80 Cr4,906.60 Cr5,197.50 Cr5,690.70 Cr
Gross Profit --------7,267.30 Cr9,289.20 Cr9,854.70 Cr11,089.20 Cr
Operating Expenses 2,394.00 Cr2,957.00 Cr2,912.00 Cr3,294.00 Cr4,121.00 Cr4,696.00 Cr5,562.00 Cr-5,640.20 Cr7,854.70 Cr8,375.40 Cr9,590.60 Cr
Operating Income 475.00 Cr141.00 Cr703.00 Cr444.00 Cr946.00 Cr1,052.00 Cr866.00 Cr-1,627.10 Cr1,434.50 Cr1,479.30 Cr1,498.60 Cr
EBITDA 696.00 Cr390.00 Cr980.00 Cr829.00 Cr1,394.00 Cr1,604.00 Cr1,581.00 Cr-2,429.20 Cr4,068.40 Cr4,471.00 Cr3,394.90 Cr
Interest Expense 9.00 Cr29.00 Cr26.00 Cr62.00 Cr71.00 Cr65.00 Cr58.00 Cr-419.00 Cr974.40 Cr897.40 Cr990.30 Cr
Pretax Income 624.00 Cr751.00 Cr850.00 Cr610.00 Cr1,215.00 Cr1,186.00 Cr1,068.00 Cr-897.10 Cr1,525.20 Cr1,886.60 Cr447.90 Cr
Tax Provision 93.60 Cr142.69 Cr161.50 Cr158.60 Cr206.55 Cr320.22 Cr224.28 Cr-254.10 Cr227.40 Cr457.20 Cr79.10 Cr
Net Income 528.00 Cr609.00 Cr688.00 Cr453.00 Cr1,003.00 Cr871.00 Cr846.00 Cr-462.70 Cr1,022.50 Cr1,013.30 Cr385.60 Cr
Diluted EPS 4.144.595.103.107.546.246.17-3.878.548.462.82

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 6,375.00 Cr8,458.00 Cr9,394.00 Cr9,990.00 Cr12,192.00 Cr14,414.00 Cr18,490.00 Cr-52,042.80 Cr56,070.70 Cr58,797.30 Cr63,650.60 Cr
Current Assets --------12,334.00 Cr15,179.20 Cr16,286.20 Cr17,179.80 Cr
Cash & Equivalents --------1,323.20 Cr1,233.40 Cr3,226.70 Cr2,416.50 Cr
Inventory --------4,243.70 Cr4,943.90 Cr4,931.10 Cr6,085.70 Cr
Receivables --------3,573.20 Cr6,230.60 Cr5,487.90 Cr5,986.80 Cr
Total Liabilities --------29,554.00 Cr30,795.90 Cr31,084.80 Cr27,029.10 Cr
Current Liabilities --------8,510.70 Cr15,358.80 Cr14,333.80 Cr14,069.20 Cr
Long Term Debt --------15,290.50 Cr12,932.40 Cr12,405.40 Cr10,746.30 Cr
Total Debt 1,117.00 Cr2,478.00 Cr2,302.00 Cr2,264.00 Cr2,422.00 Cr2,715.00 Cr4,481.00 Cr-18,018.80 Cr16,276.70 Cr18,362.00 Cr15,434.10 Cr
Total Equity 3,271.00 Cr4,034.00 Cr4,838.00 Cr5,181.00 Cr6,098.00 Cr6,706.00 Cr7,627.00 Cr-17,866.90 Cr19,783.70 Cr21,644.00 Cr34,031.80 Cr
Shares Outstanding --------120.06 Cr120.06 Cr120.06 Cr162.09 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 211.00 Cr371.00 Cr640.00 Cr662.00 Cr1,155.00 Cr1,283.00 Cr1,160.00 Cr-1,852.50 Cr2,953.90 Cr4,061.20 Cr1,994.00 Cr
Investing Cash Flow -491.00 Cr-1,138.00 Cr-510.00 Cr-684.00 Cr-703.00 Cr-1,505.00 Cr-3,651.00 Cr--14,281.80 Cr-1,004.50 Cr-234.10 Cr-2,082.10 Cr
Financing Cash Flow 186.00 Cr1,068.00 Cr-178.00 Cr-240.00 Cr-242.00 Cr388.00 Cr2,564.00 Cr-13,048.70 Cr-2,332.70 Cr-1,854.00 Cr-923.60 Cr
Capital Expenditure -838.00 Cr-617.00 Cr-608.00 Cr-913.00 Cr-1,492.00 Cr-1,829.00 Cr-1,737.00 Cr--1,726.30 Cr-1,931.60 Cr-2,343.30 Cr-1,911.70 Cr
Free Cash Flow -627.00 Cr-246.00 Cr32.00 Cr-251.00 Cr-337.00 Cr-546.00 Cr-577.00 Cr-126.20 Cr1,022.30 Cr1,717.90 Cr82.30 Cr
Net Change in Cash -94.00 Cr300.00 Cr-47.00 Cr-261.00 Cr210.00 Cr165.00 Cr72.00 Cr-619.40 Cr-383.30 Cr1,973.10 Cr-1,011.70 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------66.5%65.4%65.5%66.1%
Operating Margin % 15.4%4.2%18.1%10.8%17.2%16.7%12.1%-14.9%10.1%9.8%8.9%
Net Margin % 17.1%18.2%17.7%11.0%18.2%13.8%11.8%-4.2%7.2%6.7%2.3%
ROE % 16.1%15.1%14.2%8.7%16.4%13.0%11.1%-2.6%5.2%4.7%1.1%
ROCE % --------3.7%3.5%3.3%3.0%

Shareholding Pattern

Insiders
53.76%
Institutions
26.14%
Public Float
56.53%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BIOCON

Yahoo Finance hu, 09 Jul 2026

Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili™, a Biosimilar to Eylea® (Aflibercept)

BENGALURU, India & BRIDGEWATER, N.J., July 09, 2026--Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, today announced the publication of two important clinical studies supporting the effectivene…

Yahoo Finance Wed, 01 Jul 2026

Siddharth Mittal Appointed as Managing Director & CEO of Syngene International

Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced that Siddharth Mittal has assumed the role of Managing Director and Chief Executive Officer of the Company, effective 1 …

Yahoo Finance Sat, 09 May 2026

Biocon Ltd (BOM:532523) Full Year 2026 Earnings Call Highlights: Strong Biosimilars Growth and ...

Biocon Ltd (BOM:532523) reports robust revenue growth driven by biosimilars, strategic debt reduction, and key market expansions despite external challenges.

Yahoo Finance Mon, 04 May 2026

How The Biocon (NSEI:BIOCON) Story Is Shifting As Analysts Recut Growth And Risk Assumptions

Biocon’s fair value estimate has been trimmed slightly from ₹420.74 to about ₹416.53, signalling a modest reset in how analysts are sizing up the stock today. That shift lines up with a broader, more cautious tone in recent research on life…

Yahoo Finance Wed, 25 Feb 2026

Biocon Founder and Executive Chairperson Kiran Mazumdar-Shaw to Receive Honorary Degree from Keck Graduate Institute

Consistently featured on the Forbes’ list of The World’s Most Powerful Women since 2011, Mazumdar-Shaw will also serve as the keynote speaker at the May 16 commencement ceremony.Claremont, CA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- As part of Ke…

Yahoo Finance Fri, 13 Feb 2026

Biocon Ltd (BOM:532523) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Biocon Ltd (BOM:532523) reports a robust 9% increase in operating revenue, driven by biosimilars and generics, while navigating challenges in CRDMO and regulatory hurdles.

BIOCON — Frequently Asked Questions

What is the current share price of Biocon Limited (BIOCON)?

As of 2026-07-15 09:52 IST, Biocon Limited (BIOCON) trades at ₹434.60 on NSE. Its 52-week range is ₹338.50 to ₹437.30.

What is the market capitalisation of BIOCON?

Biocon Limited (BIOCON) has a market capitalisation of ₹70,444.65 Cr on NSE.

What is the P/E ratio of BIOCON?

BIOCON trades at a trailing price-to-earnings (P/E) ratio of 154.11. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 1.92.

Does BIOCON pay a dividend?

Biocon Limited (BIOCON) currently offers a dividend yield of 0.12%.

What is the return on equity (ROE) of BIOCON?

BIOCON has a return on equity (ROE) of 1.13%. Its return on capital employed (ROCE) is 2.90%.

Is BIOCON a good stock to buy?

This page provides a data-driven analysis of Biocon Limited (BIOCON), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space